158 related articles for article (PubMed ID: 12494890)
1. Inhibition of receptor tyrosine kinase-based signal transduction as specific target for cancer treatment.
Roussidis AE; Karamanos NK
In Vivo; 2002; 16(6):459-69. PubMed ID: 12494890
[TBL] [Abstract][Full Text] [Related]
2. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
3. Kinases as targets in the treatment of solid tumors.
Giamas G; Man YL; Hirner H; Bischof J; Kramer K; Khan K; Ahmed SS; Stebbing J; Knippschild U
Cell Signal; 2010 Jul; 22(7):984-1002. PubMed ID: 20096351
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase inhibitors as a therapeutic modality.
Levitzki A
Acc Chem Res; 2003 Jun; 36(6):462-9. PubMed ID: 12809533
[TBL] [Abstract][Full Text] [Related]
5. [Tyrosine kinase receptor-ras-ERK signal transduction pathway as therapeutic tarfet in cancer].
Leirdal M; Sioud M
Tidsskr Nor Laegeforen; 2002 Jan; 122(2):178-82. PubMed ID: 11873574
[TBL] [Abstract][Full Text] [Related]
6. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
Song L; Turkson J; Karras JG; Jove R; Haura EB
Oncogene; 2003 Jul; 22(27):4150-65. PubMed ID: 12833138
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase receptors as attractive targets of cancer therapy.
Bennasroune A; Gardin A; Aunis D; Crémel G; Hubert P
Crit Rev Oncol Hematol; 2004 Apr; 50(1):23-38. PubMed ID: 15094157
[TBL] [Abstract][Full Text] [Related]
8. Small tyrosine kinase inhibitors as key molecules in the expression of metalloproteinases by solid tumors.
Stahtea XN; Kousidou OCh; Roussidis AE; Tzanakakis GN; Karamanos NK
Connect Tissue Res; 2008; 49(3):211-4. PubMed ID: 18661345
[TBL] [Abstract][Full Text] [Related]
9. Targeting silibinin in the antiproliferative pathway.
Li L; Zeng J; Gao Y; He D
Expert Opin Investig Drugs; 2010 Feb; 19(2):243-55. PubMed ID: 20047507
[TBL] [Abstract][Full Text] [Related]
10. Imatinib as a paradigm of targeted therapies.
Druker BJ
Adv Cancer Res; 2004; 91():1-30. PubMed ID: 15327887
[TBL] [Abstract][Full Text] [Related]
11. Suppression of ARG kinase activity by STI571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/INK4c.
Nishimura N; Furukawa Y; Sutheesophon K; Nakamura M; Kishi K; Okuda K; Sato Y; Kano Y
Oncogene; 2003 Jun; 22(26):4074-82. PubMed ID: 12821941
[TBL] [Abstract][Full Text] [Related]
12. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
[TBL] [Abstract][Full Text] [Related]
14. [Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals].
Grimm CF; Blum HE; Geissler M
Dtsch Med Wochenschr; 2005 May; 130(21):1318-22. PubMed ID: 15902620
[No Abstract] [Full Text] [Related]
15. Role of tyrosine kinase inhibitors in cancer therapy.
Arora A; Scholar EM
J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
17. Effects of STI571 (gleevec) on pancreatic cancer cell growth.
Li J; Kleeff J; Guo J; Fischer L; Giese N; Büchler MW; Friess H
Mol Cancer; 2003 Sep; 2():32. PubMed ID: 14521721
[TBL] [Abstract][Full Text] [Related]
18. Parallel signaling pathways in endothelin-1-induced proliferation of U373MG astrocytoma cells.
He S; Dibas A; Yorio T; Prasanna G
Exp Biol Med (Maywood); 2007 Mar; 232(3):370-84. PubMed ID: 17327470
[TBL] [Abstract][Full Text] [Related]
19. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
20. Drug Insight: gastrointestinal stromal tumors (GIST)--the solid tumor model for cancer-specific treatment.
Sleijfer S; Wiemer E; Verweij J
Nat Clin Pract Oncol; 2008 Feb; 5(2):102-11. PubMed ID: 18235442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]